Sfoglia per Autore
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
1992 G., Orengo; E., Noviello; G., Cimoli; G., Pagnan; S., Parodi; M., Venturini; Conte, Pierfranco; F., Schenone; G., Conzi; P., Russo
Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines.
1992 P., Russo; S., Parodi; G., Billi; C., Oliva; M., Venturini; E., Noviello; Conte, Pierfranco
Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells.
1992 G., Cimoli; M., Valenti; M., Venturini; Conte, Pierfranco; P., Russo
Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
1993 G., Cimoli; M., Valenti; S., Parodi; A., Mazzoni; F. D., Sessa; Conte, Pierfranco; P., Russo
Advanced ovarian cancer. Carboplatin versus cisplatin.
1993 J. B., Vermorken; W. W., Ten; E. A., Eisenhauer; G., Favalli; D., Belpomme; Conte, Pierfranco; S. B., Kaye
The impact of received dose intensity on the outcome of advanced ovarian cancer.
1993 L., Repetto; M., Pace; S., Mammoliti; M., Bruzzone; S., Chiara; C., Oliva; T., Guido; Conte, Pierfranco; E., Campora; A., Rubagotti
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region.
1993 S., Spagnesi; F., Ducci; M., Laddaga; A., Falcone; Conte, Pierfranco; A., Pandolfi; C. G., Stampino
Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma.
1993 Conte, Pierfranco
Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications.
1993 M., Valenti; G., Cimoli; S., Parodi; G. L., Mariani; M., Venturini; Conte, Pierfranco; P., Russo
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens.
1993 S., Chiara; E., Campora; L., Merlini; C., Simoni; L., Iskra; F., Odicino; N., Ragni; Conte, Pierfranco; R., Rosso
Evaluation of taxol cardiotoxicity in metastatic breast cancer.
1993 O., Biadi; G., Mengozzi; G., Gherarducci; G., Strata; M., Mariani; F., Baldini; P. G., Giannessi; A., Surbone; Conte, Pierfranco
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study
1993 Falcone, A; Cianci, C; Ricci, S; Brunetti, I; Bertuccelli, M; Conte, Pierfranco
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients.
1993 P., Pronzato; G., Bertelli; G., Gardin; A., Rubagotti; Conte, Pierfranco; R., Rosso
Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation.
1993 M., Valenti; G., Cimoli; G. L., Mariani; Conte, Pierfranco; S., Parodi; P., Russo
Advanced epithelial ovarian cancer: 1993 consensus statements.
1993 D. G., Allen; J., Baak; D., Belpomme; J. S., Berek; K., Bertelsen; W. W., Ten; M. E., Van; A. H., Calvert; Conte, Pierfranco; J., Dauplat
Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
1994 Conte, Pierfranco; A., Gadducci; P., Fioretti; M., Bruzzone; I., Brunetti; N., Ragni
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy.
1994 S., Chiara; Conte, Pierfranco; P., Franzone; M., Orsatti; M., Bruzzone; A., Rubagotti; F., Odicino; S., Rugiati; F., Carnino; R., Rosso
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
1994 I., Brunetti; A., Falcone; M., Bertuccelli; C., Cianci; S., Ricci; Conte, Pierfranco
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.
1994 A., Falcone; R., Danesi; L., Zaccaro; D., Pieracci; E., Pfanner; C., Cianci; M., Andreuccetti; G., Malvaldi; M. D., Tacca; Conte, Pierfranco
In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma.
1994 E., Baldini; P. G., Giannessi; G., Gardin; A., Alama; F., Minuto; A., Barreca; Conte, Pierfranco
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. | 1-gen-1992 | G., Orengo; E., Noviello; G., Cimoli; G., Pagnan; S., Parodi; M., Venturini; Conte, Pierfranco; F., Schenone; G., Conzi; P., Russo | |
Potentiation by tumor necrosis factor of mitoxantrone cytotoxicity to human ovarian cancer cell lines. | 1-gen-1992 | P., Russo; S., Parodi; G., Billi; C., Oliva; M., Venturini; E., Noviello; Conte, Pierfranco | |
Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells. | 1-gen-1992 | G., Cimoli; M., Valenti; M., Venturini; Conte, Pierfranco; P., Russo | |
Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3. | 1-gen-1993 | G., Cimoli; M., Valenti; S., Parodi; A., Mazzoni; F. D., Sessa; Conte, Pierfranco; P., Russo | |
Advanced ovarian cancer. Carboplatin versus cisplatin. | 1-gen-1993 | J. B., Vermorken; W. W., Ten; E. A., Eisenhauer; G., Favalli; D., Belpomme; Conte, Pierfranco; S. B., Kaye | |
The impact of received dose intensity on the outcome of advanced ovarian cancer. | 1-gen-1993 | L., Repetto; M., Pace; S., Mammoliti; M., Bruzzone; S., Chiara; C., Oliva; T., Guido; Conte, Pierfranco; E., Campora; A., Rubagotti | |
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. | 1-gen-1993 | S., Spagnesi; F., Ducci; M., Laddaga; A., Falcone; Conte, Pierfranco; A., Pandolfi; C. G., Stampino | |
Role of anthracyclines in first line combination chemotherapy of ovarian carcinoma. | 1-gen-1993 | Conte, Pierfranco | |
Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications. | 1-gen-1993 | M., Valenti; G., Cimoli; S., Parodi; G. L., Mariani; M., Venturini; Conte, Pierfranco; P., Russo | |
Recurrent ovarian carcinoma: salvage treatment with platinum in patients responding to first-line platinum-based regimens. | 1-gen-1993 | S., Chiara; E., Campora; L., Merlini; C., Simoni; L., Iskra; F., Odicino; N., Ragni; Conte, Pierfranco; R., Rosso | |
Evaluation of taxol cardiotoxicity in metastatic breast cancer. | 1-gen-1993 | O., Biadi; G., Mengozzi; G., Gherarducci; G., Strata; M., Mariani; F., Baldini; P. G., Giannessi; A., Surbone; Conte, Pierfranco | |
Alpha-2B-interferon plus floxuridine in metastatic renal cell carcinoma. A phase I-II study | 1-gen-1993 | Falcone, A; Cianci, C; Ricci, S; Brunetti, I; Bertuccelli, M; Conte, Pierfranco | |
Analysis of time to response to chemotherapy in 316 metastatic breast cancer patients. | 1-gen-1993 | P., Pronzato; G., Bertelli; G., Gardin; A., Rubagotti; Conte, Pierfranco; R., Rosso | |
Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation. | 1-gen-1993 | M., Valenti; G., Cimoli; G. L., Mariani; Conte, Pierfranco; S., Parodi; P., Russo | |
Advanced epithelial ovarian cancer: 1993 consensus statements. | 1-gen-1993 | D. G., Allen; J., Baak; D., Belpomme; J. S., Berek; K., Bertelsen; W. W., Ten; M. E., Van; A. H., Calvert; Conte, Pierfranco; J., Dauplat | |
Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma. | 1-gen-1994 | Conte, Pierfranco; A., Gadducci; P., Fioretti; M., Bruzzone; I., Brunetti; N., Ragni | |
High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. | 1-gen-1994 | S., Chiara; Conte, Pierfranco; P., Franzone; M., Orsatti; M., Bruzzone; A., Rubagotti; F., Odicino; S., Rugiati; F., Carnino; R., Rosso | |
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. | 1-gen-1994 | I., Brunetti; A., Falcone; M., Bertuccelli; C., Cianci; S., Ricci; Conte, Pierfranco | |
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. | 1-gen-1994 | A., Falcone; R., Danesi; L., Zaccaro; D., Pieracci; E., Pfanner; C., Cianci; M., Andreuccetti; G., Malvaldi; M. D., Tacca; Conte, Pierfranco | |
In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma. | 1-gen-1994 | E., Baldini; P. G., Giannessi; G., Gardin; A., Alama; F., Minuto; A., Barreca; Conte, Pierfranco |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile